| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Channabasappa Shivaprasad | Q57335058 |
| P2093 | author name string | Sanjay Kalra | |
| P2860 | cites work | A review of the receptor-binding and pharmacokinetic properties of dopamine agonists | Q28264219 |
| A randomized, double-blind, placebo-controlled trial to assess safety and tolerability during treatment of type 2 diabetes with usual diabetes therapy and either Cycloset or placebo | Q33288874 | ||
| Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes | Q33932712 | ||
| Bromocriptine: old drug, new formulation and new indication | Q34145883 | ||
| Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes | Q34620547 | ||
| Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes | Q34718312 | ||
| Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 | ||
| Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease | Q37742798 | ||
| Bromocriptine Mesylate for Glycemic Management in Type 2 Diabetes Mellitus | Q37803304 | ||
| Dopamine: the forgotten felon in type 2 diabetes | Q37954769 | ||
| Timed bromocriptine administration reduces body fat stores in obese subjects and hyperglycemia in type II diabetics | Q41113906 | ||
| Centrally mediated effects of bromocriptine on cardiac sympathovagal balance | Q43681952 | ||
| Bromocriptine-induced reduction of body fat in pigs | Q43860922 | ||
| Does bromocriptine improve glycemic control of obese type-2 diabetics? | Q44942941 | ||
| Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects | Q47330714 | ||
| Suprachiasmatic nuclei monoamine metabolism of glucose tolerant versus intolerant hamsters | Q48151137 | ||
| Bromocriptine reduces obesity, glucose intolerance and extracellular monoamine metabolite levels in the ventromedial hypothalamus of Syrian hamsters | Q48415286 | ||
| Dopaminergic neurotoxin administration to the area of the suprachiasmatic nuclei induces insulin resistance | Q48565675 | ||
| Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes. | Q51551827 | ||
| Bromocriptine: a novel approach to the treatment of type 2 diabetes. | Q51554471 | ||
| Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemic women. | Q51573142 | ||
| Lack of evidence for bromocriptine effect on glucose tolerance, insulin resistance, and body fat stores in obese type 2 diabetic patients. | Q54044536 | ||
| Chronic ventromedial hypothalamic infusion of norepinephrine and serotonin promotes insulin resistance and glucose intolerance. | Q54063921 | ||
| Circadian neuroendocrine role in age-related changes in body fat stores and insulin sensitivity of the male Sprague-Dawley rat. | Q54233920 | ||
| Bromocriptine redirects metabolism and prevents seasonal onset of obese hyperinsulinemic state in Syrian hamsters | Q70595405 | ||
| Inhibitory effects of bromocriptine on vascular smooth muscle cell proliferation | Q73589900 | ||
| Increased responsiveness to the hyperglycemic, hyperglucagonemic and hyperinsulinemic effects of circulating norepinephrine in ob/ob mice | Q73897004 | ||
| Intracerebroventricular administration of bromocriptine ameliorates the insulin-resistant/glucose-intolerant state in hamsters | Q74625444 | ||
| P433 | issue | Suppl 1 | |
| P921 | main subject | type 2 diabetes | Q3025883 |
| P304 | page(s) | S17-24 | |
| P577 | publication date | 2011-07-01 | |
| P1433 | published in | Indian Journal of Endocrinology and Metabolism | Q15816442 |
| P1476 | title | Bromocriptine in type 2 diabetes mellitus | |
| P478 | volume | 15 |
| Q42858950 | Adrenergic India: Managing its diabetes |
| Q92220413 | Analysis of the Relationship between Type II Diabetes Mellitus and Parkinson's Disease: A Systematic Review |
| Q37474214 | Brain signaling systems in the Type 2 diabetes and metabolic syndrome: promising target to treat and prevent these diseases |
| Q51213312 | Bromocriptine treatment at the end of lactation prevents hyperphagia, higher visceral fat and liver triglycerides in early-weaned rats at adulthood. |
| Q34971736 | Cardiovascular safety profile of currently available diabetic drugs |
| Q92544135 | Circadian-timed quick-release bromocriptine lowers elevated resting heart rate in patients with type 2 diabetes mellitus |
| Q33718801 | Dopamine D2 receptors and the circadian clock reciprocally mediate antipsychotic drug-induced metabolic disturbances |
| Q36560960 | Efficacy of bromocriptine on glycemic and metabolic control of prediabetic patients |
| Q90725411 | Novel Trajectories of Bromocriptine Antidiabetic Action: Leptin-IL-6/ JAK2/p-STAT3/SOCS3, p-IR/p-AKT/GLUT4, PPAR-γ/Adiponectin, Nrf2/PARP-1, and GLP-1 |
| Q38128788 | Overview of food products and dietary constituents with antidiabetic properties and their putative mechanisms of action: a natural approach to complement pharmacotherapy in the management of diabetes |
| Q37016075 | Should depressive patients undergo a regular diabetes screening test? |
| Q40596896 | Subchronic Oral Bromocriptine Methanesulfonate Enhances Open Field Novelty-Induced Behavior and Spatial Memory in Male Swiss Albino Mice |
| Q41858733 | The dirty dozen of diabetes |
Search more.